

**WHOLE EXOME SEQUENCING (WES) REQUISITION**
**PATIENT INFORMATION (COMPLETE ONE FORM FOR EACH PERSON TESTED)**

Patient Last Name	Patient First Name	MI	/	/	Date of Birth (MM / DD / YYYY)
Address	City	State	Zip	Phone	
Accession #	Hospital / Medical Record #		Genetic Sex: <input type="radio"/> Female <input type="radio"/> Male <input type="radio"/> Unknown Gender identity (if different from above): _____		

**Note:** All reports will be sent via fax except for international recipients.

**ORDERING PHYSICIAN**
**ADDITIONAL REPORTS**

Ordering Physician	Institution Code	Name	Name
Institution Name	Email	Email	Email
Email (Required for International Clients)	Phone	Phone	Phone
Phone	Fax	Fax	Fax

**Note:** Reports will be sent by fax except for international recipients.

**PAYMENT (FILL OUT ONE OF THE OPTIONS BELOW)**

**SELF PAYMENT** .....

Pay With Sample     Bill To Patient

**INSTITUTIONAL BILLING** .....

Institution Name	Institution Code	Institution Contact Name	Institution Phone	Institution Contact Email
------------------	------------------	--------------------------	-------------------	---------------------------

**INSURANCE** .....

**Note:** Rapid Whole Exome Sequencing testing options are available exclusively under institutional billing or self-pay pricing. Insurance billing is not offered.

Do not perform test until patient is aware of out-of-pocket costs (excludes prenatal testing)

REQUIRED ITEMS	1. Copy of the Front/Back of Insurance Card(s)	2. ICD10 Diagnosis Code(s)	ICD10 Diagnosis Code(s) (Required)
	3. Name of Ordering Physician	4. Insured Signature of Authorization	

Commercial     Medicaid     Medicare\*

\*A completed Advance Beneficiary Notice (ABN) is required for Medicare patients that do not meet Medicare criteria.

Has the patient been a hospital inpatient in the last 14 days?

No, the patient was not an inpatient     Yes, the patient was an inpatient (hospital stay longer than 24 hours)

Primary Insurance Co. Name	Primary Insurance Co. Phone	Secondary Insurance Co. Name	Secondary Insurance Co. Phone
Primary Member Policy #	Primary Member Group #	Secondary Member Policy #	Secondary Member Group #
Name of Insured	Insured Date of Birth (MM / DD / YYYY)	Name of Insured	Insured Date of Birth (MM / DD / YYYY)
Patient's Relationship to Insured	Phone of Insured	Patient's Relationship to Insured	Phone of Insured
Address of Insured	City	State	Zip

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates. If self-pay is selected, I agree to pay for the cost of testing ordered and billed by Baylor Genetics as outlined in the Good Faith Estimate I received. I understand that I am responsible for sending Baylor Genetics any and all payments that I receive directly from my insurance company in payment for this test. Please note, Medicare may not cover certain screening tests.

Patient / Guardian Printed Name	Patient / Guardian Signature	/ /
		Date (MM / DD / YYYY)

## WHOLE EXOME SEQUENCING (WES) REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

### STATEMENT OF MEDICAL NECESSITY AND CONSENT TO TERMS & CONDITIONS FOR TEST ORDER (REQUIRED)

This requisition hereby incorporates the Terms and Conditions of the Laboratory Services found at <https://www.baylorgenetics.com/lab-terms-conditions/> or, in the case of international entities, <https://www.baylorgenetics.com/terms-conditions-of-the-laboratory-services-international/>. This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient, and they have consented to genetic testing.

Physician's Printed Name \_\_\_\_\_ Physician's Signature \_\_\_\_\_ Date (MM / DD / YYYY) \_\_\_\_\_

### INSTRUCTIONS FOR ORDERING

Familial samples are required for non-Proband WES. Please contact the laboratory if placing a test order where the comparator(s) are different than the required family members listed.

For select cases as determined by Baylor Genetics, WES may be supplemented by RNA Sequencing (RNA-Seq) to aid with variant classification as a standard part of this test offering. If the originally submitted specimen is blood and meets all established specimen requirements, RNA-Seq will be reflexively performed without additional authorization. If these requirements are not met, submission of a new blood specimen may be requested, or reflexive testing may not be performed. A final report will be issued prior to initiating RNA-Seq. Any updates resulting from this additional technology will be provided through an addended report.

### STANDARD WES TEST OPTIONS

- 1500 Proband Whole Exome Sequencing
- 1603 Duo Whole Exome Sequencing
- 1600 Trio Whole Exome Sequencing
- 1604 Quad Whole Exome Sequencing

Acceptable sample types for standard WES testing options include: blood in EDTA (purple-top), extracted DNA, cultured skin fibroblast, buccal swab, saliva, cord blood collected at or after birth, and skin biopsy.

CORRESPONDING COMPARATOR TESTS  
(Both Biological Parents Are Required)

- 1550 Comparator WES  
 Maternal  Paternal
- 1602 Comparator Control  
 Maternal  Paternal

CORRESPONDING COMPARATOR TESTS  
(Both Biological Parents + One Additional Family Member Are Required)

- 1550 Comparator WES  
 Maternal  Paternal
- 1602 Comparator WES  
 Sibling  Child
- Maternal:  Half-Sibling  Aunt/Uncle  
 Grandparent  First Cousin
- Paternal:  Half-Sibling  Aunt/Uncle  
 Grandparent  First Cousin

### RAPID WES TEST OPTIONS

**Note:** Rapid Whole Exome Sequencing testing options are available exclusively under institutional billing or self-pay pricing. Insurance billing is not offered.

- 1729 Rapid Proband Whole Exome Sequencing
- 1723 Rapid Duo Whole Exome Sequencing
- 1722 Rapid Trio Whole Exome Sequencing
- 1724 Rapid Quad Whole Exome Sequencing

Acceptable sample types for Rapid WES testing options include: blood in EDTA (purple-top), extracted DNA, buccal swab, and cord blood collected at or after birth.

CORRESPONDING COMPARATOR TESTS  
(Both Biological Parents + One Additional Family Member Are Required)

- 1550 Comparator WES  
 Maternal  Paternal
- 6997 Comparator Control  
 Maternal  Paternal
- 1550 Comparator WES  
 Maternal  Paternal
- 1550 Comparator WES  
 Sibling  Child
- Maternal:  Half-Sibling  Aunt/Uncle  
 Grandparent  First Cousin
- Paternal:  Half-Sibling  Aunt/Uncle  
 Grandparent  First Cousin

### ADD-ON TESTS

- 4900 Global Metabolomic Assisted Pathway Screen - Plasma from EDTA  
Was plasma extracted from EDTA?  Yes  No
- 4901 Global Metabolomic Assisted Pathway Screen - Urine
- 8665 Chromosomal Microarray Analysis (CMA)-HR+SNP Screen (Comprehensive)
- 2055 Comprehensive mtDNA analysis by NGS
- 9815 Exome Raw Data Release

**Note:** Any combination of Chromosomal Microarray Analysis (CMA), mtDNA Analysis, or Global MAPS® can be ordered along with a WES test, however the turnaround time for results will differ from exome sequencing.

## WHOLE EXOME SEQUENCING (WES) REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

### ADDITIONAL REPORTING OPTIONS

If a box is not checked the lab will default to No / Not Report.

#### Option for Reporting of ACMG Secondary Findings

Variants in genes included in the ACMG secondary findings guidelines will be reported for each family member marked below. Each marked family member will receive their own report on these findings.

- Proband   
  Mother   
  Father   
  Other Family Member

#### Option for Reporting of Incidental Findings

Pathogenic and likely pathogenic variants in genes covered under Category II of the Incidental Findings section of the consent form will be reported.

- Please report pathogenic and likely pathogenic variants in genes associated with Incidental Findings.

#### Trio and Quad Orders with Both Parents Only – Option for Reporting of Research Findings

For variants in genes with no known disease association, these variants will be reported if biallelic or de novo.

- Please report biallelic and de novo variants in genes with no known disease association.

### PROBAND SAMPLE(S)

Please refer to [www.baylorgenetics.com](http://www.baylorgenetics.com) for full sample requirements.

**Note:** Acceptable sample types for Rapid Whole Exome Sequencing test options include cord blood collected at or after birth, extracted DNA, blood in EDTA (purple-top), and buccal swab.

- |  |  |                                       |  |
|--|--|---------------------------------------|--|
| <input type="radio"/> Blood in EDTA (preferred)                | <input type="radio"/> Saliva                   | mtDNA analysis only                   | Global MAPS® only  |
| <input type="radio"/> Buccal Swab                              | <input type="radio"/> Skin Biopsy*             | <input type="radio"/> Skeletal Muscle | <input type="radio"/> Plasma from EDTA <input type="radio"/> Urine |
| <input type="radio"/> Cord Blood (collected at or after birth) | <input type="radio"/> Extracted DNA from _____ | <input type="radio"/> Liver           | _____ / _____ / _____  |
| <input type="radio"/> Cultured Skin Fibroblast                 |  | <input type="radio"/> Tissue          | Date of Collection (MM / DD / YYYY)                                |

**NOTE:** Extracted DNA/RNA will only be accepted if the isolation of nucleic acids for clinical testing occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.

### COMPARATOR INFORMATION

Comparator	Last Name	First Name	Genetic Sex	Date of Birth (MM / DD / YYYY)	Date of Collection (MM / DD / YYYY)	Sample Type	Symptomatic? (Attach summary of findings if Yes)
<b>Maternal</b>			/ /	____ / ____ / ____	____ / ____ / ____	<input type="radio"/> Blood in EDTA (preferred) <input type="radio"/> Buccal Swab <input type="radio"/> Saliva	<input type="radio"/> Yes <input type="radio"/> No
<b>Paternal</b>			/ /	____ / ____ / ____	____ / ____ / ____	<input type="radio"/> Blood in EDTA (preferred) <input type="radio"/> Buccal Swab <input type="radio"/> Saliva	<input type="radio"/> Yes <input type="radio"/> No
<b>Other Family Member:</b> <input type="radio"/> Sibling <input type="radio"/> Child  <b>Maternal</b> <input type="radio"/> Half-Sibling <input type="radio"/> Aunt/Uncle <input type="radio"/> Grandparent <input type="radio"/> First Cousin  <b>Paternal</b> <input type="radio"/> Half-Sibling <input type="radio"/> Aunt/Uncle <input type="radio"/> Grandparent <input type="radio"/> First Cousin			<input type="radio"/> Female <input type="radio"/> Male	____ / ____ / ____	____ / ____ / ____	<input type="radio"/> Blood in EDTA (preferred) <input type="radio"/> Buccal Swab <input type="radio"/> Saliva	<input type="radio"/> Yes <input type="radio"/> No

\* This sample type incurs an additional fee and typically adds 14 days to the turnaround time, depending on sample quality.  
 † Baylor Genetics will store this sample for up to 14 days after the report is issued, allowing for follow-up testing if needed.

**WHOLE EXOME SEQUENCING (WES) REQUISITION**

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

**ITEM CHECKLIST FOR TESTING**

- |  |  |  |
|--|--|--|
| <input type="checkbox"/> Proband Sample (Required) | <input type="checkbox"/> Clinical Note/Summary | <input type="checkbox"/> Pedigree (Optional) |
| <input type="checkbox"/> Comparator Samples        | <input type="checkbox"/> Requisition           |  |
| <input type="checkbox"/> Signed WES Consent Form   | <input type="checkbox"/> Indication for Study  |  |

**INDICATION FOR TESTING (REQUIRED)**

Please provide the following clinical information regarding the patient to be tested. Please also submit a clinic note and pedigree, if available. Phenotypes listed are in HPO terms with the corresponding HPO number (<http://human-phenotype-ontology.github.io/>). This information is needed to facilitate interpretation of whole exome sequencing results. If the laboratory requires additional information, please indicate the health care provider to be contacted:

**PRE/PERINATAL HISTORY** .....

- 0001622 Prematurity - GA at birth \_\_\_\_\_
- 0001511 Intrauterine Growth Restrictions
- 0001562 Oligohydramnios
- 0001561 Polyhydramnios
- 0000476 Cystic Hygroma
- 0000776 Congenital Diaphragmatic Hernia
- 0001508 Failure to Thrive
- 0001539 Omphalocele
- 0002084 Encephalocele
- 0010880 Increased Nuchal Translucency
- \_\_\_\_\_

**EYE DEFECTS & VISION** .....

- 0000505 Visual Impairment
- 0000618 Blindness
- 0000589 Coloboma
- 0000526 Aniridia
- 0000528 Anophthalmia
- 0000568 Microphthalmia
- 0000508 Ptosis
- 0000486 Strabismus
- 0000519 Cataract Congenital Bilateral
- \_\_\_\_\_
- \_\_\_\_\_

**MOTOR/COGNITIVE DEVELOPMENT** .....

- 0000750 Delayed Speech & Language Development
- 0001270 Delayed Motor Milestones
- 0002376 Developmental Regression
- Intellectual Disability
  - 0001256 Mild
  - 0002342 Moderate
  - 0010864 Severe
- 0000729 Autistic Spectrum Disorder
- \_\_\_\_\_
- \_\_\_\_\_

**STRUCTURAL BRAIN ABNORMALITIES** .....

- 0001360 Holoprosencephaly
- 0001339 Lissencephaly
- 0002084 Encephalocele
- 0000238 Hydrocephalus
- 0002119 Ventriculomegaly
- 0001273 Abnormality of Corpus Callosum
- 0002539 Cortical Dysplasia
- 0012444 Brain Atrophy
- 0002352 Leukoencephalopathy
- 0002269 Abnormality of Neuronal Migration
- 0002126 Polymicrogyria
- 0001302 Pachgyria
- 0002500 Abnormality of Cerebral White Matter
- 0007266 Cerebral Dysmyelination
- 0006808 Cerebral Hypomyelination
- 0002134 Abnormality of the Basal Ganglia
- 0002363 Abnormality of the Brainstem
- 0007360 Aplasia/Hypoplasia of the Cerebellum
- 0006817 Aplasia/Hypoplasia of the Cerebellar Vermis
- \_\_\_\_\_

**NEUROLOGICAL** .....

- 0001284 Areflexia
- 0200134 Epileptic Encephalopathy
- 0001250 Seizures
  - 0002373 Febrile Seizures
  - 0012469 Infantile Spasms
  - 0002123 Generalized Myoclonic Seizures
  - 0002069 Generalized Tonic-clonic Seizures
  - 0010818 Generalized Tonic Seizures
  - 0010819 Atonic Seizures
  - 0002121 Absence Seizures
  - 0011169 Generalized Clonic Seizures
  - 0001251 Ataxia
  - 0001332 Dystonia
  - 0002072 Chorea
  - 0001257 Spasticity
  - 0009830 Neuropathy
- \_\_\_\_\_
- \_\_\_\_\_

**CRANIOFACIAL** .....

- 0000256 Macrocephaly
- 0000252 Microcephaly
- 0001363 Craniosynostosis
- 0000204 Cleft Upper Lip
- 0000175 Cleft Palate
- 0000316 Hypertelorism
- 0000601 Hypotelorism
- 0008050 Abnormality of the Palpebral Fissures
- 0000286 Epicanthal Folds
- 0000288 Abnormality of the Philtrum
- 0010938 Abnormality of the External Nose
- \_\_\_\_\_
- \_\_\_\_\_

Indications continued on next page

**WHOLE EXOME SEQUENCING (WES) REQUISITION**

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

**INDICATION FOR TESTING (REQUIRED) - CONTINUED**
**HAIR & SKIN** .....

- 0000957 Cafe-Au-Lait Spots
- 0001034 Hypermelanotic Macule
- 0001010 Hypopigmentation of the Skin
- 0008066 Abnormal Blistering of the Skin
- 0008064 Ichthyosis
- 0000988 Skin Rash
- 0001581 Recurrent Skin Infections
- 0005306 Capillary Hemangiomas
- 0001597 Abnormality of the Nail
- 0004554 Generalized Hypertrichosis
- 0001596 Alopecia
- 0002208 Coarse Hair
- 0002299 Brittle Hair
- \_\_\_\_\_
- \_\_\_\_\_

**CARDIAC** .....

- 0001631 Atria Septal Defect
- 0001629 Ventricular Septal Defect
- 0001655 Patent Foramen Ovale
- 0001713 Abnormality of Cardiac Ventricle
- 0001636 Tetralogy of Fallot
- 0001680 Coarctation of Aorta
- 0001647 Bicuspid Aortic Valve
- 0002616 Aortic Root Dilatation
- 0001638 Cardiomyopathy
- 0011675 Arrhythmia
- \_\_\_\_\_
- \_\_\_\_\_

**GENITOURINARY** .....

- 0000113 Polycystic Kidney Dysplasia
- 0000107 Renal Cyst
- 0008738 Partially Duplicated Kidney
- 0000104 Renal Agenesis
- 0000085 Horseshoe Kidney
- 0000069 Abnormality of the Ureter
- 0000795 Abnormality of the Urethra
- 0000047 Hypospadias
- 0000028 Cryptorchidism
- 0000035 Abnormality of the Testis
- 0000062 Ambiguous Genitalia
- \_\_\_\_\_
- \_\_\_\_\_

**RESPIRATORY** .....

- 0002093 Respiratory Insufficiency
- 0002878 Respiratory Failure
- 0002104 Apnea
- 0002791 Hypoventilation
- 0002883 Hyperventilation
- 0002788 Recurrent Upper Respiratory Tract Infections
- \_\_\_\_\_
- \_\_\_\_\_

**METABOLIC** .....

- 0001946 Ketosis
- 0003074 Hyperglycemia
- 0001943 Hypoglycemia
- 0001941 Acidosis
- 0003128 Lactic Acidosis
- 0003215 Dicarboxylic Aciduria
- 0002490 Increased CSF lactate
- 0001992 Organic Aciduria
- 0030085 Abnormal CSF Lactate Level
- 00003542 Increased Serum Pyruvate
- 0003535 3-Methylglutaconic aciduria
- 0001942 Metabolic acidosis
- 0100493 Hypoammonemia
- 0001987 Hyperammonemia
- 0004923 Hyperphenylalaninemia
- 0003234 Decreased Plasma Carnitine
- 0003236 Elevated Serum Creatine Phosphokinase
- Abnormal Newborn Screen
- Unusual Color/Odor
- \_\_\_\_\_
- \_\_\_\_\_

**MUSCULOSKELETAL** .....

- 0011398 Hypotonia
- 0001276 Hypertonia
- 0000098 Tall Stature
- 0004322 Short Stature
- 0001382 Joint Hypermobility
- 0001371 Flexion Contracture
- 0002804 Arthrogryposis Multiplex Congenita
- 0001161 Hand Polydactyly
- 0001829 Foot Polydactyly
- 0006101 Finger Syndactyly
- 0001770 Toe Syndactyly
- 0100490 Camptodactyly of Finger
- 0012165 Oligodactyly
- 0001762 Talipes Equinovarus
- 0002757 Recurrent Fractures
- 0002650 Scoliosis
- 0002808 Kyphosis
- 0003307 Hyperlordosis
- 0001528 Hemihypertrophy
- 0001513 Obesity
- 0001548 Overgrowth
- 0002652 Skeletal Dysplasia
- \_\_\_\_\_
- \_\_\_\_\_

**GASTROINTESTINAL** .....

- 0002021 Pyloric Stenosis
- 0002575 Tracheoesophageal Fistula
- 0002032 Esophageal Atresia
- 0002020 Gastroesophageal Reflux
- 0001733 Pancreatitis
- 0002014 Diarrhea
- 0002019 Constipation
- 0002037 Inflammatory Bowel Disease
- 0004389 Intestinal Pseudo-Obstruction
- 0001399 Hepatic Failure
- 0002572 Episodic Vomiting
- 0001744 Splenomegaly
- 0002240 Hepatomegaly
- 0001508 Postnatal Failure to Thrive
- 0002578 Gastroparesis
- \_\_\_\_\_
- \_\_\_\_\_

Indications continued on next page

**WHOLE EXOME SEQUENCING (WES) REQUISITION**

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

**INDICATION FOR TESTING (REQUIRED) - CONTINUED**
**ENDOCRINE** .....

- 0000819 Diabetes Mellitus
- 0000873 Diabetes Insipidus
- 0000821 Hypothyroidism
- 0000829 Hypoparathyroidism
- 0000834 Abnormality of the Adrenal Glands
- 0001738 Exocrine Pancreatic Insufficiency
- 0002721 Immunodeficiency
- \_\_\_\_\_
- \_\_\_\_\_

**EAR DEFECTS & HEARING** .....

- 0000407 Sensorineural Hearing Impairment
  - 0008619 Bilateral
- 0000405 Conductive Hearing Impairment
- 0000410 Mixed Hearing Impairment
- 0004467 Preauricular Pit
- 0000384 Preauricular Skin Tag
- 0000369 Low-set Ears
- 000037 Abnormality of the Pinna
- \_\_\_\_\_
- \_\_\_\_\_

**HEMATOLOGY** .....

- 0001875 Neutropenia
  - 0005549 Congenital
  - Chronic
  - Cyclic
- 0001873 Thrombocytopenia
- 0040185 Macrothrombocytopenia
- 0005537 Decreased Mean Platelet Volume
- 0005518 Erythrocyte Macrocytosis
- 0004444 Spherocytosis
- 0012410 Pure Red Cell Aplasia
  - Aplastic
  - Hypoplastic
- 0001903 Anemia
- 0005528 Bone Marrow Hypocellularity
- \_\_\_\_\_
- \_\_\_\_\_

**CANCER** .....

- Type of Cancer \_\_\_\_\_
- Age of Diagnosis \_\_\_\_\_
- Family History of Cancer and Affected Relatives \_\_\_\_\_
- \_\_\_\_\_
- \_\_\_\_\_

**OTHER** .....

- Organomegaly
- Chronic Infections
- 0004311 Abnormality of Macrophages
- 0001954 Episodic Fever
- 0004313 Hypogammaglobulinemia
- 0010701 Abnormal Immunoglobulins
- 0002721 Immunodeficiency
- 0012088 Abnormal urinary odor
- 0012537 Food intolerance
- 0008067 Abnormally lax or hyperextensible skin
- Abnormal Movements
- Family History of Similar Disorder
- 0001254 Lethargy
- 0002415 Leukodystrophy
- \_\_\_\_\_
- \_\_\_\_\_

**GENES OF INTEREST** .....

 \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

**ADDITIONAL CLINICAL INFORMATION**
**DIFFERENTIAL DIAGNOSIS**

Consent on next page

## INFORMED CONSENT FOR WHOLE EXOME SEQUENCING (WES)

For the purposes of this consent, "you", "me", "my", and "I" can also mean your child (including unborn child) or the individual you are the personal representative for.

\_\_\_\_\_  
Patient Last Name

\_\_\_\_\_  
Patient First Name

\_\_\_\_\_  
MI

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
Date of Birth (MM / DD / YYYY)

\_\_\_\_\_  
Genetic Sex

### WHOLE EXOME SEQUENCING (WES) AND WHOLE EXOME SEQUENCING (WES) CONSENT

This consent form can only be used for whole exome sequencing and Whole Exome Sequencing. Consent forms for other tests are located at Baylor Genetics' website (<https://www.baylorgenetics.com/consent/>).

For the purposes of this consent, "I", "my", "you", and "your" can refer to you, your child, your unborn child, or other individual you are the legal representative of.

### TEST INFORMATION

Your healthcare provider (doctor, genetic counselor, or other person with medical training) wants to order a genetic test called Whole Exome Sequencing (WES) or Whole Exome Sequencing (WES). These tests look for changes, called variants, in a person's DNA that can cause health issues. DNA is our genetic material. These variants can be in certain genes, specific parts of our DNA that are needed for our health. They can also be found in other places in the genome (all DNA that a person has). Based on your known health issues, variants in your DNA that may cause these issues will be reported. This test may explain your health issues. It may also explain health issues that your family may have. Even if this test finds the cause of your health issues, this may not help treat or manage those issues.

Testing where your DNA is compared to one or more family members may be performed. This may help better understand your results or show if your family members have the same variant as you.

Before you sign this consent form, you should speak with your healthcare provider. They can help you understand this testing and what it means for your health.

### TEST RESULTS

There are several types of test results that may be reported including:

- **Positive:** A variant in the DNA was found that is related to your health issues or a health issue that you are at an increased risk of having in the future. These changes that cause disease are also known as pathogenic variants.
- **Negative:** No variants in the DNA were found that are related to your health issues or that would increase your risk of a health issue in the future.
- **Variant of Uncertain Clinical Significance (VUS):** A variant in the DNA was found that we do not know its effect, if any, on health. More testing may be needed for you or your family if a VUS is found that may be associated with your health issues.
- **Secondary and Incidental Findings (Optional):** Testing can sometimes find a variant in the DNA not related to the reason for testing but can change your medical care. **Note:** Certain issues within the brain start in adulthood and get worse over time (neurodegenerative). They often have no cure or treatment. By default, these variants will not be reported unless they are related to your health issues. However, variants in one or more of these gene(s) can be requested if needed. Your provider must write each gene needed in your test order.
- **Genes of No Known Disease Association (Optional):** Testing may find a variant in a gene that is not known to cause disease. This may be helpful to learn more about these genes in the future. These results do not currently impact medical management or indicate a diagnosis.

### SECONDARY AND INCIDENTAL FINDINGS

The following categories of variants are not expected to cause your current health issues. However, they can each be requested to be reported. Knowing about these variants might affect your future medical care.

- **ACMG Secondary Findings:** The American College of Medical Genetics and Genomics (ACMG) recommends reporting disease-causing variants in certain genes that cause health issues. Each family member can request this group of variants to be reported.
- **Incidental Findings:** Other variants known to cause health issues but that are not causing your current health issues.

### CONSIDERATIONS AND LIMITATIONS

- You should speak with your provider before signing this consent form to understand the risks, benefits, and alternatives to testing.
- Testing may show you have, or are at increased chance of having, a health issue. It may show that you have an increased chance of having a child with a health issue.
- Even if the variant(s) causing your health issues are found, how these issues might progress or improve with treatment might not be known. Affected family members with the same variant might not be affected like you are.
- Depending on the results of testing, more testing may be needed to understand these results. This testing might be needed for you and/or other family members.
- A negative result does not rule out the chance for health issues. Our knowledge of variants and how they cause disease may change over time as we learn more about genetics. Testing has limitations to what it can find as well.
- Certain factors may lead to incorrect results. These include mislabeled samples, incorrect information in the test order, and rare technical errors.
- More sample may be needed from you if the first sample is not sufficient to complete testing.

### USE OF DATA AND SPECIMEN FOR RESEARCH PURPOSES

Biological specimens, test results, and associated information may be used by Baylor Genetics and its research partners for anonymous or coded research purposes, including improving genetic testing, advancing knowledge of genetic conditions, and developing new technologies, including inclusion in de-identified clinical databases, only with the patient's informed consent. Patient data and specimen will not be used for anonymous or coded research, unless authorized by marking below. A patient's decision to decline participation shall not affect their ability to receive testing from Baylor Genetics.

For Oregon patients, please consult the state specific consent form found at [www.baylorgenetics.com/forms](http://www.baylorgenetics.com/forms).

I authorize Baylor Genetics the use of my specimen and de-identified data for research.

### FOR SAMPLES FROM NEW YORK STATE RESIDENTS

Samples from New York State residents shall not be included in research without written consent. Samples will not be retained for more than sixty (60) days after receipt by Baylor Genetics, unless authorized by marking below. No tests other than those authorized shall be performed on the samples.

I authorize Baylor Genetics to retain sample(s) longer based on our retention policy for test development, quality assurance, and training purposes.

**INFORMED CONSENT FOR WHOLE EXOME SEQUENCING (WES)**

For the purposes of this consent, "you", "me", "my", and "I" can also mean your child (including unborn child) or the individual you are the personal representative for.

Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD / YYYY)	Genetic Sex
-------------------	--------------------	----	--------------------------------	-------------

**PATIENT CONFIDENTIALITY AND SAMPLE RETENTION**

- If several family members are tested, knowing the correct biological relationships among them is important. In rare cases, testing can show that family members are not related as expected. If this is found, we may contact the provider who ordered your testing.
- If this testing is requested to be cancelled after the order and sample are sent to the laboratory, please see our Test Cancellation Policy at [www.baylorgenetics.com/cancel-test/](http://www.baylorgenetics.com/cancel-test/).

**PATIENT CONFIDENTIALITY AND SAMPLE RETENTION (CONTINUED)**

- Only Baylor Genetics and its contracted partners will have access to your sample for the ordered testing. Results from testing will only be released to: (i) a licensed healthcare provider, (ii) those authorized in writing, (iii) the patient or their personal representative, and (iv) those allowed access to test results by law. You have the right to access your test results from Baylor Genetics by providing a written request. You also have the right to request raw data obtained from your sample by providing a written request or HIPAA Authorization Form.
- In rare cases, people with genetic diseases may have problems with health insurance and employment. The U.S. Federal Government has several laws that prohibit discrimination based on test results by health insurance companies and employers. These laws also prohibit unauthorized disclosure of this information. For more information, please visit [www.genome.gov/10002077](http://www.genome.gov/10002077).
- Samples will be kept in the laboratory based on our retention policy. Once testing is completed, the de-identified sample may be used for test development, quality assurance, and training purposes. Samples are not returned to patients or providers unless requested prior to testing. You and your heirs will not receive payments, benefits, or rights to any resulting products or discoveries.
- The information from your testing may be used in scientific research, publications or presentations, but your specific identity will not be revealed. We may contact your provider to obtain more clinical information about you. Baylor Genetics also performs other types of scientific research and may contact you to see if you would like to be involved.
- Variants found may be submitted to databases. The medical community uses these databases to collect information about how variants might cause disease to improve testing and treatment for patients. An example is ClinVar, a free, public archive of reports on human genetics. Limited clinical information may need to be shared with these databases. In rare cases, this information may be enough to allow you or your family members to be identified.
- For more information on privacy practices at Baylor Genetics, please visit [www.baylorgenetics.com/privacy-practices/](http://www.baylorgenetics.com/privacy-practices/).

**FINANCIAL AGREEMENT**

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates. I designate Baylor Genetics as my designated representative for purposes of appealing any denial of benefits by my insurance carrier. I irrevocably assign associated payment to Baylor Genetics, and direct that payment be made directly to Baylor Genetics. Please note, some payers may not cover certain screening tests.

If my health insurer does not cover the test or I do not have health insurance, I have received a good faith estimate of the cost for the genetic testing ordered by my provider and agree to pay for the cost of the genetic testing billed to me by Baylor Genetics based on that good faith estimate. More information is available in Baylor Genetics' No Surprises Act and Good Faith Estimate Notice located at <https://www.baylorgenetics.com/no-surprises-act/>.

A Medicare Advance Beneficiary Notice (ABN) is required for services Medicare identifies as not medically necessary.

**PATIENT AUTHORIZATION**

By signing this statement of consent, I acknowledge that I have read, understand, and hereby grant my informed consent for genetic testing. I have received appropriate explanations from my healthcare provider about the planned genetic test(s) and possible results. I have been informed by my healthcare provider about the availability and importance of genetic counseling and have been provided with written information identifying a genetic counselor or medical geneticist who can provide such counseling services. All my questions have been answered, and I have had the necessary time to make an informed decision about the genetic test(s).

**Note: If Prenatal WES was ordered, please leave the Patient section blank and complete only a section for each relative tested below.**

I hereby give permission to Baylor Genetics to conduct genetic testing as recommended by my healthcare provider.\*

Patient Name	Patient Signature	Date Signed (MM / DD / YYYY)
--------------	-------------------	------------------------------

Relationship to Patient	Name	Signature	Date
<b>Relative 1</b>	_____	_____	_____
<b>Relative 2</b>	_____	_____	_____
<b>Relative 3</b>	_____	_____	_____

**If one or more family members have a Representative signing on their behalf:**

Name	Signature	Date (MM / DD / YYYY)	Representative For	Relationship to Represented Person(s)
------	-----------	-----------------------	--------------------	---------------------------------------

\*If you are signing on behalf of the patient as the parent(s) and/or person with legal authority to act on behalf of the patient or parent, you may be required to provide evidence of your authority.

**INFORMED CONSENT FOR WHOLE EXOME SEQUENCING (WES)**

For the purposes of this consent, "you", "me", "my", and "I" can also mean your child (including unborn child) or the individual you are the personal representative for.

\_\_\_\_\_  
Patient Last Name      Patient First Name      MI      Date of Birth (MM / DD / YYYY)      Genetic Sex

**FOR SURROGATES PREGNANCIES – FOR PRENATAL WES ONLY:**

Maternal cell contamination (MCC) studies use blood or another sample from a pregnant person. MCC studies are used to determine that the sample being tested belongs to the fetus and not the pregnant person. The results of MCC studies are not used for the treatment or management of the fetus, pregnant person, or other individuals, and are not part of the pregnant person's designated medical record.

I hereby give permission for my sample to be used for MCC studies:

\_\_\_\_\_  
Surrogate Name      Surrogate Signature      Date Signed (MM / DD / YYYY)